Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Assesment of Markers of Endothelial Dysfunction and Myocardial Stress in Patients with Hypertrophic Cardyomyopathy

https://doi.org/10.20996/1819-6446-2021-06-06

Full Text:

Abstract

Aim. To study the level of serum biomarkers of endothelial dysfunction and myocardial stress in patients with various types of hypertrophic cardiomyopathy (HCM).

Material and Methods. 48 patients with hypertrophic cardiomyopathy (27 men and 21 women) were examined, the mean age was 54±13 years. The patients were divided into two groups according to the course options: group 1 - symptomatic stable course (n=14); group 2 - progressive course of symptomatic HCM (n=34). In accordance with the assigned tasks, all patients underwent determination of biological markers of neurohumoral systems in blood serum using immunofluorescence assay analysis: N-terminal fragment of brain natriuretic peptide (NT-proBNP), von Willebrand factor (vWF), endothelin-1, E-selectin with subsequent evaluation and correlation of results with clinical and instrumental characteristics of patients. When performing echocardiography following parameters were assessed: dimensions of the heart chambers, the thickness of the interventricular septum, the thickness of the posterior wall of the left ventricle (LV), LV mass, LV mass index, the ratio between LV filling in diastole (peak E) and atrial systole (peak A)-(E/A), relative myocardial thickness index, left atrial volume index.

Results. Both groups showed increased levels of NT-proBNP and endothelin-1. E-selectin and vonWillebrand factor remained within the normal range. There was no statistically significant intergroup difference. There was a correlation between the level of the index of the relative myocardial thickness and the level of NT-proBNP (r=0.30; p=0.04). A correlation was found between the level of the vWF marker and the left atrial volume index (r=0.32; p=0.04). When assessing the association of indicators of intracardiac hemodynamics with other markers (E-selectin and endothelin-1, no statistically significant relationships were found.

Conclusion. In the course of the research, it was found that the high activity of endothelin-1 and NT-proBNP reflects endothelial dysfunction and myocardial stress in patients with HCM, especially in patients with a progressive variant of HCM. However, we did not find any changes in the levels of E-selectin and von Willebrand factor, as well as their intergroup differences. These results require additional studies to assess endothelial dysfunction in patients with HCM.

About the Authors

F. M. Bogatyreva
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Fatima M. Bogatyreva



V. Yu. Kaplunova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Vera Yu. Kaplunova



M. V. Kozhevnikova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Maria V. Kozhevnikova - eLibrarySPIN 8501-9812



G. A. Shakaryants
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Gayane A. Shakaryants - eLibrary SPIN 9983-1746



D. A. Yatsenko
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation


А. V. Emelianov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation


A. S. Lishuta
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Alexey S. Lishuta - eLibrary SPIN 4365-4788



N. V. Khabarova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation


E. V. Privalova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Elena V. Privalova



Yu. N. Belenkov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Yurii N. Belenkov



References

1. Russian Clinical Recommendation of Hypertrophic cardiomyopathy, 2020. Russian Society of Cardiology [cited by Feb 1 0, 2021]. Available from: https://scardio.ru/content/Guidelines/2020/ Clinic_rekom_Kardiomiopatiya.pdf (In Russ.) Доступно из: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_Kardiomiopatiya.pdf].

2. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;1 42(25):e533-e557. DOI:10.1161/CIR.0000000000000938.

3. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy J Am Coll Cardiol. 2015;65(1 2):1249-54. DOI:10.1016/j.jacc.2015.01.019.

4. Antunes de OM, Scudeler TL. Hypertrophic cardiomyopathy Int J Cardiol Heart Vasc. 2020;27:1 00503. DOI:10.1016/j.ijcha.2020.100503.

5. Konukoglu D, Uzun H. Endothelial Dysfunction and Hypertension. Adv Exp Med Biol. 2017;956:51 1 -540. DOI:10.1007/5584_2016_90.

6. Van der Velden J, Tocchetti CG, Varricchi G, et al. Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology Cardiovasc Res. 2018;1 14(10):1273-80. DOI:10.1093/cvr/cvy147.

7. Olivotto I, d'Amati G, Basso C, et al. Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations. Cardiovascular Research. 2015;105(4):409-23. DOI:10.1093/cvr/cvv024.

8. Wang Y Tang Y Zou Y et al. Plasma level of big endothelin-1 predicts the prognosis in patients with hypertrophic cardiomyopathy, Int J Cardiol. 2017;243:283-9. DOI:10.1016/j.ijcard.2017.03.162.

9. Tanaka A, Yuasa S, Mearini G, et al. Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes. J Am Heart Assoc. 2014;3(6):e001263. DOI:10.1161/JAHA.114.001263.

10. Neubauer S, Kolm P, Y Ho C, et al. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry J Am Coll Cardiol. 2019;74(19):2333-45. DOI:10.1016/j.jacc.2019.08.1057.

11. Becker RC, Owens AP III, Sadayappan S. The potential roles of Von Willebrand factor and neutrophil extracellular traps in the natural history of hypertrophic and hypertensive cardiomyopathy. Thromb Res. 2020;1 92:78-87. DOI:10.1016/j.thromres.2020.05.003.

12. Zhito AV, Iusupova AO, Kozhevnikova MV, et al. E-Selectin as a Marker of Endothelial Dysfunction in Patients With Coronary Artery Disease Including Those With Type 2 Diabetes Mellitus. Kardiologiia. 2020;60(4):24-30 (In Russ.) DOI:10.18087/cardio.2020.4.n1066.

13. Dimitrow PP, Undas A, Bober M, et al. Plasma biomarkers of endothelial dysfunction in patients with hypertrophic cardiomyopathy Pharmacol Rep. 2007;59:71 5-20.

14. Varol E, Ozaydin M, Sahin M,et al. vWf levels as a circulating marker of endothelial dysfunction in patients with hypertrophic cardiomyopathy. Indian Heart J 2005;57:655-7.

15. Cambronero F, Vilchez JA, Garcia-Honrubia A, et al. Plasma levels of von Willebrand factor are increased in patients with hypertrophic cardiomyopathy. Thromb Res. 2010;126(1 ):e46-50. DOI:10.1016/j.thromres.2010.01.010.

16. Leitner GC, Schmetterer L, Kapiotis S, Jilma B. Effects of endothelin-1 and phenylephrine on plasma levels of von Willebrand factor and protein S. Thromb Res. 2010;125(1 ):e5-8. DOI:10.1016/j.thromres.2009.08.004.


For citation:


Bogatyreva F.M., Kaplunova V.Yu., Kozhevnikova M.V., Shakaryants G.A., Yatsenko D.A., Emelianov А.V., Lishuta A.S., Khabarova N.V., Privalova E.V., Belenkov Yu.N. Assesment of Markers of Endothelial Dysfunction and Myocardial Stress in Patients with Hypertrophic Cardyomyopathy. Rational Pharmacotherapy in Cardiology. 2021;17(3):408-413. (In Russ.) https://doi.org/10.20996/1819-6446-2021-06-06

Views: 85


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)